Aktis Oncology (NASDAQ:AKTS) Shares Down 3.7% - Here's Why

Key Points

• Shares fell 3.7% intraday to about $16.73 on Monday, trading just 24,411 shares — roughly 93% below the stock's average daily volume.
• Analyst sentiment is bullish: five firms have initiated coverage with Buy/Outperform/Overweight ratings and the consensus price target is $32.00.
• Significant insider buying: Bioventures and Ecor1 Capital bought large blocks at $18 per share (more than 3.3 million combined on Jan. 12), and insiders have purchased 6,117,776 shares (~$110.1M) in the past 90 days.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) shares traded down 3.7% during mid-day trading on Monday . The stock traded as low as $16.71 and last traded at $16.7250. 24,411 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 368,978 shares. The stock had previously closed at $17.37.

Analyst Ratings Changes

AKTS has been the topic of a number of recent research reports. Leerink Partners began coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set an "outperform" rating and a $31.00 target price on the stock. Bank of America assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued a "buy" rating and a $34.00 price objective on the stock. JPMorgan Chase & Co. began coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued an "overweight" rating and a $30.00 price objective on the stock. Wall Street Zen upgraded shares of Aktis Oncology to a "hold" rating in a research note on Saturday, January 17th. Finally, TD Cowen assumed coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a "buy" rating on the stock. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $32.00.

Aktis Oncology Stock Performance

The firm has a 50-day moving average of $18.94.

Insider Activity at Aktis Oncology

In other news, major shareholder Bioventures 2018 L.P. Mpm bought 1,112,777 shares of the business's stock in a transaction dated Monday, January 12th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the transaction, the insider owned 10,260,064 shares of the company's stock, valued at approximately $184,681,152. This trade represents a 12.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ecor1 Capital, Llc bought 2,222,222 shares of the firm's stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $39,999,996.00. Following the completion of the transaction, the director owned 4,348,658 shares in the company, valued at approximately $78,275,844. This trade represents a 104.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have bought 6,117,776 shares of company stock valued at $110,119,968. Corporate insiders own 3.30% of the company's stock.

About Aktis Oncology

Aktis Oncology NASDAQ: AKTS is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.